Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-01-31 8:41 pm Purchase | 2021-12-31 | 13G | Chimerix, Inc. CMRX | Opaleye Management Inc. | 5,580,000 6.400% | 1,623,500 (+41.03%) | Filing History |
| 2022-01-31 8:38 pm Sale | 2021-12-31 | 13G | Ocular Therapeutix, Inc. OCUL | Opaleye Management Inc. | 5,974,800 7.800% | -535,200 (-8.22%) | Filing History |
| 2022-01-26 11:06 am Unchanged | 2021-12-31 | 13G | SANUWAVE Health, Inc. SNWV | Opaleye Management Inc. | 83,810 6.500% | 0 (Unchanged) | Filing History |
| 2022-01-26 11:00 am Sale | 2021-12-31 | 13G | Adamas Pharmaceuticals, Inc. ADMS | Opaleye Management Inc. | 0 0.000% | -1,487,800 (Position Closed) | Filing History |
| 2022-01-25 9:43 pm Purchase | 2021-12-31 | 13G | Harrow Health, Inc. HROW | Opaleye Management Inc. | 3,285,000 12.200% | 219,584 (+7.16%) | Filing History |
| 2022-01-24 4:05 pm Sale | 2021-12-31 | 13G | Eton Pharmaceuticals, Inc. ETON | Opaleye Management Inc. | 2,385,000 9.690% | -1,307,700 (-35.41%) | Filing History |
| 2021-06-17 4:40 pm Purchase | 2020-12-31 | 13G | Eton Pharmaceuticals, Inc. ETON | Opaleye Management Inc. | 3,692,700 15.070% | 52,700 (+1.45%) | Filing History |
| 2021-02-12 5:20 pm Sale | 2020-12-31 | 13G | Stereotaxis, Inc. STXS | Opaleye Management Inc. | 3,021,436 4.100% | -1,091,064 (-26.53%) | Filing History |
| 2021-02-12 5:20 pm Sale | 2020-12-31 | 13G | Edap Tms S.a. EDAP | Opaleye Management Inc. | 657,500 2.260% | -1,127,500 (-63.17%) | Filing History |
| 2021-02-12 5:20 pm Purchase | 2020-12-31 | 13G | SANUWAVE Health, Inc. SNWV | Opaleye Management Inc. | 83,810 6.730% | 44,562 (+113.54%) | Filing History |
| 2021-02-12 5:20 pm Purchase | 2020-12-31 | 13G | Chimerix, Inc. CMRX | Opaleye Management Inc. | 3,956,500 6.320% | 813,600 (+25.89%) | Filing History |
| 2021-02-12 5:20 pm Purchase | 2020-12-31 | 13G | Infinity Pharmaceuticals, Inc. INFIQ | Opaleye Management Inc. | 3,171,800 4.940% | 171,400 (+5.71%) | Filing History |
| 2021-02-12 5:20 pm Purchase | 2020-12-31 | 13G | Adamas Pharmaceuticals, Inc. ADMS | Opaleye Management Inc. | 1,487,800 5.220% | 61,800 (+4.33%) | Filing History |
| 2021-02-12 5:20 pm Purchase | 2020-12-31 | 13G | Harrow Health, Inc. HROW | Opaleye Management Inc. | 3,065,416 11.910% | 3,065,416 (New Position) | Filing History |
| 2021-02-12 5:20 pm Purchase | 2020-12-31 | 13G | Cardiff Oncology, Inc. CRDF | Opaleye Management Inc. | 1,662,500 4.710% | 414,500 (+33.21%) | Filing History |
| 2021-02-12 5:20 pm Sale | 2020-12-31 | 13G | Avenue Therapeutics, Inc. ATXI | Opaleye Management Inc. | 0 0.000% | -920 (Position Closed) | Filing History |
| 2021-02-12 5:20 pm Purchase | 2020-12-31 | 13G | Fortress Biotech, Inc. FBIO | Opaleye Management Inc. | 259,167 4.150% | 4,160 (+1.63%) | Filing History |
| 2021-02-12 5:20 pm Purchase | 2020-12-31 | 13G | TRACON Pharmaceuticals, Inc. TCON | Opaleye Management Inc. | 125,919 17.040% | 125,919 (New Position) | Filing History |
| 2021-02-12 5:20 pm Purchase | 2020-12-31 | 13G | FS DEV CORP COM FSDC | Opaleye Management Inc. | 704,400 5.630% | 36,000 (+5.39%) | Filing History |
| 2021-02-12 5:20 pm Sale | 2020-12-31 | 13G | Semler Scientific, Inc. SMLR | Opaleye Management Inc. | 290,500 4.360% | -43,000 (-12.89%) | Filing History |